Since NLR is a prognostic factor independent of putative clinical variables in lower-grade gliomas, and predicts survival in 4 tumor subtypes (triple-negative, IDH and TERT mutations, IDH mutation only, and TERT mutation only), this hematological marker is proposed to further stratify the prognosis of these 4 molecular groups. The gene discussed is IDH2; the disease is neoplasm.